MedPath

Study of Early Hormone Replacement Therapy on Risk Factors for Sudden Cardiac Death

Completed
Conditions
Menopausal Women
Registration Number
NCT00580775
Lead Sponsor
Yale University
Brief Summary

As an ancillary study to the KEEPS study (see ClinicalTrials.gov Identifier: NCT00154180), the primary purpose is to measure effects of estrogen vs. placebo in menopausal women, on autonomic function and repolarization; both measured non-invasively via holter monitoring.

Detailed Description

The parent study KEEPS, will be a randomized, placebo-controlled double blinded, prospective trial with two active groups and one placebo group. Only patients enrolled in KEEPS will be invited to participate in this ancillary study.Duration of the KEEPS study will be for 4 years after randomization for each study subject, with assessment of the primary endpoint, carotid CIMT, twice at baseline, 12, 24, 36 and 48 months. Ancillary to the KEEPS study, patients will undergo holter monitoring at baseline, 24 and 48 months.Data will be analyzed after 24 and 48 months (corresponding to data analysis of the primary endpoints.) Holter monitors will be put on during the scheduled KEEPS visits, will be worn for 24 hours and will be returned the following day. Effects of estrogen on heart rate variability (HRV) and repolarization parameters will be evaluated, and also correlated with clinical, quality of life, sleep and mood information gathered through the parent study. Anticipated enrollment from the parent study at this site is 90 study subjects. This ancillary does not involve the use of drugs or investigational devices.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
25
Inclusion Criteria
  • participant of the KEEPS parent study: ClinicalTrials.gov Identifier NCT00154180
Exclusion Criteria
  • non-participants of parent study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Heart rate variability48 Months
Secondary Outcome Measures
NameTimeMethod
Repolarization parameters48 Months

Trial Locations

Locations (1)

Yale University School of Medicine / Yale New Haven Hospital

🇺🇸

New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath